[VIEW] agent=Risk & Compliance Officer | scenario_id=120 | rounds=20

--- Round 0 ---
[R0.1] Risk & Compliance Officer (speak, public): To ensure we're aligned on the telehealth anticoagulation management service launch, can we start by discussing the current state of clinical effectiveness and operational scale? I'd also appreciate insights on funding and incentive alignment from the finance perspective.
[R0.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): The pilot for our telehealth anticoagulation management service has shown promising results. We had 180 patients across 2 clinics, and saw an improvement in time in therapeutic range (TTR) from 52% to 68%. We estimate that there are about 640 eligible patients per quarter, with a pilot enrollment rate of 28%.
[R0.3] Payer Contracting & Finance Manager (speak, public): The reimbursement model we're considering is based on a per-episode payment of $62, with a projected volume of 9,600 episodes per year. We've also observed a baseline of 3.4 warfarin-related ED visits per 1,000 members per month, with an average allowed amount of $1,980. I'd like to understand more about the operational scale and any potential legal or vendor terms that could impact our contracting process.

--- Round 1 ---
[R1.1] Risk & Compliance Officer (speak, public): We've made good progress understanding the clinical effectiveness and operational scale. To further assess organizational risk, can you both help me understand any tight external deal constraints we might be facing, and how we operationally handle high-risk clinical situations?
[R1.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): To address the tight external deal constraints, I believe the reimbursement model shared by the Payer Contracting & Finance Manager provides a good foundation. However, I'd like to understand more about the regulatory guardrails and security posture of any external platforms we might be using. Additionally, it would be helpful to know if there are any unresolved internal risk concerns that could impact our clinical workflow.
[R1.3] Payer Contracting & Finance Manager (speak, public): To better understand the operational scale and potential legal or vendor terms, can you share more about the clinical dosing rules and staffing intensity required for this program? Additionally, are there any hidden patient-safety exposures we should be aware of?

--- Round 2 ---
[R2.1] Risk & Compliance Officer (speak, public): To address your questions, I'll provide some information on clinical dosing rules and staffing intensity. Our telepharmacy operating rule allows for remote dosing with a pharmacist-to-tech ratio of 1:4. Regarding external deal constraints, I'd like to share that we've conducted vendor security due diligence on the home INR platform, which scored 78/100 in our security assessment. The SOC 2 Type II report is 19 months old, and we're working on updating it. Additionally, our Business Associate Agreement (BAA) with the vendor is version 3, with 2 open clauses related to breach notice and subcontractor reporting.
[R2.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): I appreciate the information shared about the telepharmacy operating rule, vendor security due diligence, and BAA details. To further assess our readiness, can you share any unresolved internal risk concerns that might impact our clinical workflow? Additionally, I'd like to understand any commercial constraints that could influence our decision to launch the telehealth anticoagulation management service.
[R2.3] Payer Contracting & Finance Manager (speak, public): Based on the information shared, it seems we have a good understanding of the clinical and operational aspects. From a financial perspective, I'd like to summarize that our projected revenue is approximately $595,200 per year based on the $62 per-episode reimbursement and 9,600 episodes. We also have the potential for a $250,000 quality incentive if we meet the TTR threshold. Our estimated total program cost is $940,000 per year, with staffing being the major component at $690,000. I believe we should discuss the financial viability and potential contract terms further.

--- Round 3 ---
[R3.1] Risk & Compliance Officer (speak, public): To further assess our readiness for the telehealth anticoagulation management service launch, I'd like to follow up on the external deal constraints and operational handling of high-risk clinical situations. Can you provide more details on any contractual obligations or limitations with our vendors or payers that might impact our operational scale or financial sustainability?
[R3.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): To address the remaining concerns, I'd like to share some additional insights from our pilot. Our staffing model is based on 1.8 pharmacist FTE and 0.6 RN FTE per 500 active patients. We've also seen high patient satisfaction, with an overall rating of 4.6/5 and only 6% reporting connectivity issues. I believe this information can help us better understand our operational capacity and potential areas for improvement.
[R3.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 4 ---
[R4.1] Risk & Compliance Officer (speak, public): To further assess our readiness for the telehealth anticoagulation management service launch, I'd like to summarize the key points discussed so far. We've covered clinical effectiveness, operational scale, funding and incentive alignment, and some aspects of external deal constraints. However, I still need more information on how we operationally handle high-risk clinical situations. Can you provide more details on this aspect?
[R4.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): To address the operational handling of high-risk clinical situations, we have implemented a protocol where an INR ≥4.5 triggers same-day clinician outreach, and a repeat test is ordered within 24 hours. While I can share that we've had positive outcomes in managing these situations, I'd like to understand if there are any remaining internal risk concerns that we haven't yet addressed.
[R4.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 5 ---
[R5.1] Risk & Compliance Officer (speak, public): To summarize our discussion on the telehealth anticoagulation management service launch, we've covered key aspects including clinical effectiveness, operational scale, funding and incentive alignment, and external deal constraints. We've also discussed the operational handling of high-risk clinical situations. Based on the information shared, I believe we have a comprehensive understanding of the service's readiness. I recommend proceeding with the launch, provided that we continue to monitor and address any emerging risks. I'd like to thank both of you for your insights and collaboration.
[R5.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): I appreciate your summary and recommendation to proceed with the launch of the telehealth anticoagulation management service. I believe we've made significant progress in understanding the clinical effectiveness, operational scale, and financial sustainability of the service. However, I'd like to confirm that we've addressed all the key aspects before making a final decision.
[R5.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 6 ---
[R6.1] Risk & Compliance Officer (leave, public): 
[R6.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R6.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 7 ---
[R7.1] Risk & Compliance Officer (leave, public): 
[R7.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R7.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 8 ---
[R8.1] Risk & Compliance Officer (leave, public): 
[R8.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R8.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 9 ---
[R9.1] Risk & Compliance Officer (leave, public): 
[R9.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R9.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 10 ---
[R10.1] Risk & Compliance Officer (leave, public): 
[R10.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R10.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 11 ---
[R11.1] Risk & Compliance Officer (leave, public): 
[R11.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R11.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 12 ---
[R12.1] Risk & Compliance Officer (leave, public): 
[R12.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R12.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 13 ---
[R13.1] Risk & Compliance Officer (leave, public): 
[R13.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R13.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 14 ---
[R14.1] Risk & Compliance Officer (leave, public): 
[R14.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R14.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 15 ---
[R15.1] Risk & Compliance Officer (leave, public): 
[R15.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R15.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 16 ---
[R16.1] Risk & Compliance Officer (leave, public): 
[R16.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R16.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 17 ---
[R17.1] Risk & Compliance Officer (leave, public): 
[R17.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R17.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 18 ---
[R18.1] Risk & Compliance Officer (leave, public): 
[R18.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R18.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 19 ---
[R19.1] Risk & Compliance Officer (leave, public): 
[R19.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R19.3] Payer Contracting & Finance Manager (leave, public): 

